CLYM
Climb Bio, Inc.Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-06-11 |
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
Data demonstrate favorable safety and tolerability profile, robust B - cell depletion, and encouraging platelet responses in heavily pretreated patients with primary immune thrombocytopenia Enrollment ongoing in the high dose cohort, with additional data anticipated by year-end 2026 WELLESLEY |
| 2026-06-05 |
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026 WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. |
| 2026-05-26 |
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal |
| 2026-05-14 |
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology |
| 2026-05-12 |
Climb Bio to Present at Upcoming Investor Conferences
WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences |
| 2026-05-07 |
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical |
| 2026-05-05 |
Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts
Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast Track Designation received for pMN Initial data from ITP trial anticipated in June; initial data |
| 2026-04-28 |
Climb Bio, Inc. Announces $110.0 Million Private Placement
WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional |
| 2026-04-08 |
Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026
WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&D Spotlight Series - a budoprutug webcast event, which |
| 2026-04-07 |
Climb Bio Announces FDA Fast Track Designation for Budoprutug for the Treatment of Primary Membranous Nephropathy
Global Phase 2 open-label clinical trial in pMN (PrisMN) enrolling, with initial data anticipated H2 2026 WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated |
Past events
| Date | Event | Type |
|---|---|---|
| 2026-06-04 | Jefferies Global Healthcare Conference | Conference |
| 2026-06-04 | Jefferies Global Healthcare Conference Click here for webcast | Conference |
| 2026-05-19 | H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ | Conference |
| 2026-05-19 | H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ Click here for webcast | Conference |
| 2026-05-05 | R&D Spotlight: Budoprutug and the CD19 Opportunity | Event |
| 2026-05-05 | R&D Spotlight: Budoprutug and the CD19 Opportunity Click here for webcast | Webcast |
| 2026-03-09 | Leerink Global Healthcare Conference | Conference |
| 2026-02-25 | Oppenheimer 36th Annual Healthcare Life Sciences Conference | Conference |
| 2026-02-12 | Guggenheim's Emerging Outlook: Biotech Summit | Event |
| 2025-12-02 | Piper Sandler’s 37th Annual Healthcare Conference | Conference |
| 2025-11-18 | Baird Biotech Discovery Series | Event |
| 2025-11-10 | Guggenheim’s 2nd Annual Healthcare Innovation Conference | Conference |
| 2025-09-29 | CLYM116 and the IgA Nephropathy (IgAN) Opportunity | Event |
Source: https://ir.climbbio.com/